Adverse Alterations in Mitochondrial Function Contribute to Type 2 Diabetes Mellitus–Related Endothelial Dysfunction in Humans

Tinoy J. Kizhakekuttu,* Jingli Wang,* Kodlipet Dharmashankar, Rong Ying, David D. Gutterman, Joseph A. Vita, Michael E. Widlansky

Objective—Mitochondrial dysfunction plays a key pathophysiological role in type 2 diabetes mellitus (T2DM). Data delineating relationships between mitochondrial and endothelial dysfunction in humans with T2DM are lacking.

Methods and Results—In 122 human subjects (60 with T2DM, 62 without T2DM), we measured endothelial function by brachial artery ultrasound (flow mediated dilation) and digital pulse amplitude tonometry. Endothelial function in arterioles isolated from gluteal subcutaneous adipose was measured by videomicroscopy. In arterioles and mononuclear cells, we measured inner mitochondrial membrane potential (Δψm), mitochondrial mass, and mitochondrial superoxide production using fluorophores. Endothelial function was impaired in T2DM subjects versus control subjects. Δψm magnitude was larger and mitochondrial mass was lower in arterioles and mononuclear cells in T2DM. Mononuclear mitochondrial mass correlated with flow-mediated dilation and pulse amplitude tonometry (ρ=0.38 and 0.33, P=0.001 and 0.02, respectively), and mononuclear mitochondrial superoxide production inversely correlated with flow-mediated dilation (ρ=−0.58, P=0.03). Low doses of 2 different mitochondrial uncoupling agents (carbonyl cyanide m-chlorophenyl hydrazone and 2,4-dinitrophenol) that reduce Δψm magnitude and a mitochondrial-targeted antioxidant (MitoTEMPO) improved endothelial function and reduced mitochondrial superoxide levels in T2DM arterioles.

Conclusion—Mitochondrial dysfunction may play a central role in the impairment of endothelial dysfunction in T2DM. (Arterioscler Thromb Vasc Biol. 2012;32:2531-2539.)

Key Words: diabetes mellitus type 2 ▪ endothelium ▪ mitochondria ▪ NO ▪ oxidative stress

The worldwide incidence of type 2 diabetes mellitus (T2DM) is expected to exceed 350 million people in 2030, with the incidence rate of T2DM increasing in all segments of the population.1,5 The majority of morbidity and mortality related to diabetes mellitus is secondary to the macrovascular (myocardial infarctions, stroke) and microvascular (blindness, renal failure) complications of this disease.2,3 The pathogenesis of clinically overt vascular disease in T2DM, while not completely elucidated, seems to begin with the initial development of vascular endothelial dysfunction.4-8 Endothelial dysfunction encompasses the provasoconstrictive, prothrombotic, and proinflammatory endothelial phenotype known to precede the development of clinically relevant vascular disease and portend future cardiovascular risk.9,10

The molecular origins of insulin-resistance–related vascular endothelial dysfunction include the induction of excessive oxidative stress7,11 and the activation of proinflammatory and provasoconstrictive pathways involving nuclear factor-κB and protein kinase C-β.12-14 Hyperglycemia and excess circulating free fatty acids seem to be responsible for the initiation of vascular oxidative stress and inflammation.15,16 Interestingly, in cell culture models, activation of these deleterious pathways also seems to require the development of mitochondrial dysfunction.17,18 Based on prior cell culture and animal work, insulin-resistance–related mitochondrial dysfunction is typified by 2 key alterations in the mitochondrial phenotype that lead to excessive mitochondrial reactive oxygen species (ROS) production: inner mitochondrial membrane hyperpolarization19,20 and reduced mitochondrial mass and mitochondrial network complexity.20-22 We recently observed such alterations in mitochondrial function and morphology in peripheral blood mononuclear cells and isolated venous endothelial cells from patients with T2DM.20,23

Excessive mitochondrial ROS production is known to cause deleterious vascular cell signaling and subsequent endothelial dysfunction.24 Despite cell and animal data supporting...
a potential role for mitochondrial dysfunction in the origins of vascular dysfunction in T2DM, there are no data linking mitochondrial dysfunction to vascular endothelial dysfunction in intact human arteries and arterioles. We hypothesized that (1) systemic measurements of arterial endothelial function would correlate with systemic measurements of mitochondrial homeostasis derived from circulating mononuclear cells; (2) arteries of patients with T2DM would display phenotypic mitochondrial dysfunction, with reduced mitochondrial mass and greater mitochondrial inner membrane polarization relative to nondiabetic humans; and (3) mitochondrial hyperpolarization and excessive mitochondrial superoxide production would relate mechanistically to arteriolar endothelial dysfunction in patients with T2DM.

Methods

Subjects
The study protocol and advertisements were approved by the Medical College of Wisconsin’s Institutional Research Board. The inclusion/exclusion criteria for nondiabetic subjects and T2DM subjects were previously described.20 A total of 122 individuals between 35 and 70 years of age were consecutively enrolled. We previously reported mitochondrial membrane potential, mass, and superoxide production in 59 of these subjects (27 subjects with T2DM, 32 with non-T2DM).25 For T2DM subjects, the additional cohort of 33 subjects had slightly higher systolic blood pressure (131±2 versus 125±8 mm Hg, \[P=0.02\], heart rate (70±2 versus 64±5 bpm, \[P=0.04\]), and fasting triglycerides (151±14 versus 125±9, \[P=0.02\]) but otherwise did not differ with respect to other baseline characteristics as shown in the Table. There were no significant differences in the baseline characteristics of the additional 30 non-T2DM subjects. Subjects were defined as having T2DM based on standard criteria.25 Nondiabetic control subjects were excluded if they met criteria for metabolic syndrome,26 had a history of cardiovascular disease by history or documentation in patients with T2DM.27 For T2DM subjects, the additional cohort of 33 subjects had slightly higher systolic blood pressure (131±2 versus 125±8 mm Hg, \[P=0.02\]), heart rate (70±2 versus 64±5 bpm, \[P=0.04\]), and fasting triglycerides (151±14 versus 125±9, \[P=0.02\]) but otherwise did not differ with respect to other baseline characteristics as shown in the Table. There were no significant differences in the baseline characteristics of the additional 30 non-T2DM subjects. Subjects were defined as having T2DM based on standard criteria.25 Nondiabetic control subjects were excluded if they met criteria for metabolic syndrome,26 had a history of cardiovascular disease by history or documented myocardial infarction,27 had a major chronic illness, were pregnant at the time of screening, or had smoked within 1 year of enrollment. All subjects fasted for at least 6 hours before their study visits, and all studies began between 7:30 AM and 9:00 AM. Subjects on antihypertensive medications were asked to hold these medications for at least 6 hours before their study visits. Subjects on oral diabetes mellitus medications were instructed to hold their morning pills until completion of the study protocol. All subjects had blood drawn for measurements of fasting glucose levels, lipid profiles, measurements of insulin resistance, and measurements of mitochondrial homeostasis. Insulin resistance was estimated using both homeostasis model assessment-insulin resistance=\([\text{fasting insulin} \times \text{fasting glucose mmol/L}] / 22.5\) and the quantitative insulin-sensitivity check index=\(1/\log(\text{insulin})+\log(\text{glucose})\).

Materials
Acetylcholine (Ach), 2.4 dinitrophenol (DNP)—reduces mitochondrial membrane potential magnitude, \(\Delta \psi_m\), carbonyl cyanide m-chlorophenyl hydrazone (CCCP)—also reduces \(\Delta \psi_m\), and L-Nω-nitroarginine methyl ester (L-NAME—NO synthase inhibitor) were purchased from Sigma-Aldrich (St. Louis, MO). 5,5′,6,6′-tetrachloro-1,1′,3′,3′-tetraethylbenzamidazol-carbocyanine (JC-1—measures \(\Delta \psi_m\), magnitude), acridine orange 10-nonyl bromide (NAO—measures mitochondrial cardiolipin content as a marker of mitochondrial mass), MitoSox, diaminofluorescein diacetate (DAF-2DA—measures NO bioavailability), and tetramethylrhodamine methyl ester (TMRM—measures \(\Delta \psi_m\)) were purchased from Invitrogen (Carlsbad, CA). MitoTEMPOL was purchased from Enzo Life Sciences International, Inc (Plymouth Meeting, PA).

<table>
<thead>
<tr>
<th>Subject Characteristics</th>
<th>Type 2 Diabetes Mellitus (n=60)†</th>
<th>No Diabetes Mellitus (n=62)†</th>
<th>(P) Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age</td>
<td>Age 52±9</td>
<td>49±8</td>
<td>0.08</td>
</tr>
<tr>
<td>Sex (% Female)</td>
<td>Sex 67</td>
<td>65</td>
<td>0.80</td>
</tr>
<tr>
<td>Race (% Black)</td>
<td>Race 30</td>
<td>11</td>
<td>0.009</td>
</tr>
<tr>
<td>Body mass index, kg/m²</td>
<td>Body mass index 34.6±8.0</td>
<td>28.2±5.6</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Smoking status, % (Previous)</td>
<td>Smoking status 37</td>
<td>31</td>
<td>0.48</td>
</tr>
<tr>
<td>Family history of CAD, %</td>
<td>Family history 37</td>
<td>20</td>
<td>0.03</td>
</tr>
<tr>
<td>Waist circumference, cm</td>
<td>Waist circumference 111±17</td>
<td>94±16</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Systolic blood pressure, mm Hg</td>
<td>Systolic blood pressure 128±29</td>
<td>125±19</td>
<td>0.46</td>
</tr>
<tr>
<td>Diastolic blood pressure, mm Hg</td>
<td>Diastolic blood pressure 72±10</td>
<td>73±12</td>
<td>0.29</td>
</tr>
<tr>
<td>Heart rate, beats/min</td>
<td>Heart rate 70±12</td>
<td>65±10</td>
<td>0.28</td>
</tr>
<tr>
<td>Total cholesterol, mg/dL</td>
<td>Total cholesterol 179±33</td>
<td>188±38</td>
<td>0.67</td>
</tr>
<tr>
<td>LDL cholesterol, mg/dL</td>
<td>LDL cholesterol 98±30</td>
<td>114±30</td>
<td>0.01</td>
</tr>
<tr>
<td>HDL cholesterol, mg/dL</td>
<td>HDL cholesterol 51±14</td>
<td>56±15</td>
<td>0.08</td>
</tr>
<tr>
<td>Triglycerides, mg/dL</td>
<td>Triglycerides 152±73</td>
<td>95±36</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Glucose, mg/dL</td>
<td>Glucose 134±52</td>
<td>82±11</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Insulin, μU/mL</td>
<td>Insulin 20±11</td>
<td>13±8</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>hs-CRP, mg/dL</td>
<td>hs-CRP 4.1±4.4</td>
<td>2.6±3.5</td>
<td>0.04</td>
</tr>
<tr>
<td>HOMA-IR</td>
<td>HOMA-IR 7.0±5.2</td>
<td>2.9±2.1</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>QUICKI</td>
<td>QUICKI 0.30±0.06</td>
<td>0.34±0.03</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Glycosylated hemoglobin, %</td>
<td>Glycosylated hemoglobin 6.8±1.6</td>
<td>5.6±1.0</td>
<td>0.006</td>
</tr>
</tbody>
</table>

CAD indicates coronary artery disease; LDL, low-density lipoprotein; HDL, high-density-lipoprotein; hs-CRP, high sensitivity C-reactive protein; HOMA-IR, homeostasis model assessment-insulin resistance; QUICKI, quantitative insulin-sensitivity check index.
†n=59 for waist circumference, 59 for glucose, 58 for insulin, 56 for hs-CRP, and 23 for glycosylated hemoglobin.

Measurements of In Vivo Endothelial Function

Brachial Artery Reactivity Testing
We measured flow-mediated dilation (FMD%), nitroglycerin-mediated dilation (NMD%), flow velocity, and shear stress in the brachial artery as previously described.26 We recorded average diameter of the entire R-R interval and used these measurements to calculate both FMD% and NMD%. For FMD%, our intra- and interobserver correlation coefficients are 0.99 and 0.87, respectively. The mean absolute difference measured between observers is 1.0±0.8%.

Digital Pulse Amplitude Tonometry
Digital pulse amplitude was measured using a pulse amplitude tonometry (PAT) device placed on the index finger of each hand (Endo-PAT 2000; Itamar Medical, Caesarea, Israel). We measured and reported PAT as the natural log of the ratio of the baseline pulse amplitudes and postdeflation pulse amplitudes 90 to 120 seconds after cuff deflation as described previously.4 Greater detail on the methods for PAT can be found in the online-only Data Supplement.

Measurement of In Vitro Endothelial Function

Please see the online-only Data Supplement for full methodological details on the procedure used to obtain human gluteal adipose arterioles and preparation of these vessels for study of endothelium-dependent and independent vasodilation by videomicroscopy. Our success rate for obtaining usable arterioles for study by biopsy was 75%. As each biopsy yielded ≈1 usable arteriole, we could
not perform all measurements on all vessels. The type of study done
with each vessel was randomly selected and stratified by study group.
Endothelium-dependent vasodilation was determined at increasing
concentrations of Ach from 10⁻¹⁰ to 10⁻⁸ mol/L. Endothelial NO
synthase dependence of vasodilation was determined by concomitant
L-NAME exposure (1 mmol/L). To determine whether partial depo-
larization of the mitochondrial inner membrane altered endothelial
function, vessels were additionally exposed (intraluminally) to either
CCCP (100 nmol/L) or DNP (50 nmol/L) for 30 minutes before mea-
surements of Ach-induced vasodilation (flow rate < 5 dynes/cm²).
To determine whether lowering mitochondrial superoxide levels
improved endothelial function, a subset of vessels were intralumi-
nally exposed to MitoTEMPOL (1 mmol/L) for 30 minutes before
measuring Ach-induced vasodilation. All vessels were exposed to
0.2 mol/L papaverine at the end of each study to determine the level
of endothelium-independent vasodilation.

Vascular Measurements of Mitochondrial Homeostasis

**NAO and JC-1 Arteriolar Endothelium Measurements**

Following dissection, cannulation, and equilibration, NAO (25
nmol/L), JC-1 (100 nmol/L), or TMRM (1 µmol/L) was allowed to
flow through the vascular lumen for 30 minutes at a low rate (shear
< 5 dynes/cm²). Before fluorophore exposure, arterioles to be exposed
to NAO and TMRM were imaged by fluorescent microscopy to
serve as negative controls. To verify the endothelial specificity of
our studies with NAO and JC-1, we denuded several vessels with air
boluses (3 for each fluorophore) before visualization and imaged ves-
sels that were not exposed to fluorophores as well. Sample images
and results confirming the endothelial specificity of these studies
are shown in Figures I and II in the online-only Data Supplement.
NAO and TMRM fluorescence intensities were measured by fluo-
rescent microscopy (Eclipse TE 200; Nikon, Japan) with Ex/Em of
492/526 nm and 549/573 nm, respectively. Reported NAO and
TMRM fluorescence intensities are the net of the NAO- or TMRM-
exposed arteriole from each individual minus the individual’s
matched control fluorescence intensity. Red and green JC-1 fluores-
cence were detected by inverted laser scanning confocal microscopy
(Eclipse TE2000-U; Nikon, Tokyo, Japan) with Ex/Em of 488/520
nm and 578 nm. All fluorescence intensities in this study were ana-
yzed using MetaMorph 6.1 (Universal Imaging, West Chester, PA).

**MitoSox and DAF2-DA Measurements on Arterioles**

From Subjects With and Without T2DM

Arterioles were incubated in HEPES buffer under normal glucose
conditions (5 mmol/L) with either MitoSox (5 µmol/L) or DAF2-DA
(5 µmol/L) for 30 minutes. MitoSox fluorescence intensity was mea-
sured by fluorescent microscopy (Eclipse TE 200; Nikon, Japan)
at Ex/Em of 510/572 nm for MitoSox or 492/526 nm for DAF2-DA.
Negative control images from the same vessels were taken before giv-
ing fluorescent dye. Reported MitoSox and DAF2-DA fluorescence
intensities are the net of the MitoSox- or DAF2-DA-exposed arteriole
from each individual minus the individual’s matched negative control
vessel background fluorescence.

**Systemic Measurements of Mitochondrial Homeostasis**

Measurements of mitochondrial superoxide production using
MitoSox, mitochondrial membrane potential (∆Ψm) using JC-1,
and mitochondrial cardiolipin content as a measure of mitochon-
drial mass using NAO were performed in mononuclear cells isolated
from venous blood of subjects with and without T2DM as previously
described. Reproducibility of both JC-1 and NAO measurements in
human mononuclear cells using these assays has been previously
described. Because of limitations on the amount of cells available
each patient for the studies presented, MitoSox (n=13), JC-1
(n=95), and NAO (n=71) were only performed on a subset of the full
study population.

**Statistical Analyses**

Baseline characteristics, measurements of mitochondrial homeo-
statics in both mononuclear cells and arterioles, and in vivo vascu-
lar endothelial function for nondiabetic subjects and subjects with
T2DM were compared using unpaired t tests, Wilcoxon rank-sum
tests, or χ² tests as appropriate. Correlations between mononuclear
and results confirming the endothelial specificity of
these studies
are shown in Figures I and II in the online-only Data Supplement.
NAO and TMRM fluorescence intensities are the net of the NAO- or TMRM-
exposed arteriole from each individual minus the individual’s
matched control fluorescence intensity. Red and green JC-1 fluores-
cence were detected by inverted laser scanning confocal microscopy
(Eclipse TE2000-U; Nikon, Tokyo, Japan) with Ex/Em of 488/520
nm and 578 nm. All fluorescence intensities in this study were ana-
yzed using MetaMorph 6.1 (Universal Imaging, West Chester, PA).

**MitoSox and DAF2-DA Measurements on Arterioles**

From Subjects With and Without T2DM

Arterioles were incubated in HEPES buffer under normal glucose
conditions (5 mmol/L) with either MitoSox (5 µmol/L) or DAF2-DA
(5 µmol/L) for 30 minutes. MitoSox fluorescence intensity was mea-
sured by fluorescent microscopy (Eclipse TE 200; Nikon, Japan)
at Ex/Em of 510/572 nm for MitoSox or 492/526 nm for DAF2-DA.
Negative control images from the same vessels were taken before giv-
ing fluorescent dye. Reported MitoSox and DAF2-DA fluorescence
intensities are the net of the MitoSox- or DAF2-DA-exposed arteriole
from each individual minus the individual’s matched negative control
vessel background fluorescence.

**Systemic Measurements of Mitochondrial Homeostasis**

Measurements of mitochondrial superoxide production using
MitoSox, mitochondrial membrane potential (∆Ψm) using JC-1,
and mitochondrial cardiolipin content as a measure of mitochon-
drial mass using NAO were performed in mononuclear cells isolated
from venous blood of subjects with and without T2DM as previously
described. Reproducibility of both JC-1 and NAO measurements in
human mononuclear cells using these assays has been previously
described. Because of limitations on the amount of cells available
each patient for the studies presented, MitoSox (n=13), JC-1
(n=95), and NAO (n=71) were only performed on a subset of the full
study population.

**Results**

**Subject Characteristics**

A total of 136 subjects were screened, and 14 potential non-
diabetic participants were excluded because of screening
failures, leaving 122 subjects for study. The baseline charac-
teristics of T2DM and nondiabetic subjects are delineated
in the Table. Overall, we found no significant differences in age,
sex, smoking status, blood pressure, heart rate, total cho-
lesterol, and high-density lipoprotein cholesterol between the
2 groups. Patients with T2DM were more likely to be black
and have a family history of coronary artery disease. Patients
with T2DM also had a significantly larger waist circumference,
body mass index, higher fasting insulin and glucose levels,
greater insulin resistance as measured by homeostasis model
assessment-insulin resistance and quantitative insulin-
sensitivity check index, and higher serum C-reactive protein
levels. Low-density lipoprotein cholesterol levels were lower in patients with T2DM likely secondary to concomitant
3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitor
therapy. The breakdown of medications taken by the T2DM
and nondiabetic subjects is delineated in Table I in the online-
only Data Supplement.

**Systemic Measurements of Mitochondrial Homeostasis and Their Associations**

With Systemic Endothelial Function

In a subset of 71 of the 122 subjects (35 nondiabetic, 36
diabetic), we measured NAO fluorescence intensity in
mononuclear cells. We measured mitochondrial mem-
brane potential in a subset of 95 of the 122 subjects (46
nondiabetic, 49 diabetic). As we previously reported in
a smaller set of these subjects, NAO fluorescence intensity
was significantly lower in patients with T2DM than controls
(235±19 versus 127±17 AU for nondiabetic subjects
versus subjects with T2DM, P<0.001), and mitochondrial
membrane potential was significantly more polarized in
T2DM subjects relative to nondiabetic subjects (13.1±0.8 versus 17.4±0.9 for nondiabetic subjects versus subjects with T2DM, P<0.001). We have also previously reported excess mitochondrial superoxide production in T2DM subjects relative to nondiabetic subjects in a subset of this population. Interestingly, we now found a strong negative correlation between paired measurements of mononuclear cell NAO fluorescence intensity and MitoSox fluorescence intensity (n=13, ρ=−0.72, P=0.006; Figure III in the online-only Data Supplement).

Results of systemic measures of endothelial function in both T2DM and non-T2DM subjects are summarized in Table II in the online-only Data Supplement. FMD% (6.2±1.6 versus 3.7±1.7%, P<0.001) and ln PAT (0.74±0.61 versus 0.48±0.42, P=0.02) were significantly lower in patients with T2DM. There was a trend toward reduced nitroglycerin-mediated dilation in T2DM (NMD%: 21.9±7.0% versus 19.5±6.3%, P=0.07; NMD mm: 0.82±0.26 versus 0.73±0.21, P=0.05). We found no differences in baseline peak shear (42±15 versus 40±14 dynes/cm² for non-T2DM and T2DM, respectively, P=0.36) or peak hyperemic shear (78±28 versus 71±23 dynes/cm² for non-T2DM and T2DM, respectively, P=0.09) between groups.

We report significant univariate correlations between systemic measurements of endothelial function and monocyte mitochondrial homeostasis in Figure 1. NAO fluorescence intensity positively correlated with FMD%, PAT, and NMD% (model β=0.69, P<0.001; Figure 1A–1C). Mitochondrial superoxide production was inversely associated with FMD% (ρ=−0.18, −0.29, P=0.13, 0.33). The correlation between JC-1 fluorescence and FMD% was not significant (ρ=−0.06, P=0.59).

In stepwise multivariable linear regression models for FMD% and ln PAT, only NAO fluorescence (β=0.22 and 0.27, P=0.047 and 0.045 for FMD% and ln PAT, respectively) and fasting glucose (β=−0.40 and −0.29, P=0.001 and 0.03 for FMD% and ln PAT, respectively) remained independent predictors of FMD% (model R²=0.23, P<0.001) and ln PAT (model R²=0.20, P=0.004). No single variable was an independent predictor of NMD%. In a multivariable analysis for independent predictors of FMD% including MitoSox fluorescence rather than NAO fluorescence, only MitoSox fluorescence (β=−0.73, P=0.003) and total cholesterol (β=−0.44, P=0.046) were independent predictors (model R²=0.60, P=0.006).

Mitochondrial Dysfunction in Arterioles From Patients With T2DM

We measured mitochondrial mass, Δψm, and mitochondrial superoxide production in subcutaneous arterioles from random subsets of our study participants (Figure 2). Mitochondrial mass as measured by NAO fluorescence intensity was significantly lower in the arteriolar endothelium of subjects with T2DM (54±24 versus 199±58 AU for T2DM [n=10] and nondiabetic subjects [n=11], respectively; Figure 2A), whereas Δψm was higher in the endothelium of subjects with T2DM as measured by JC-1 (2.62±0.08 versus 1.91±0.06 for T2DM [n=5] and nondiabetic subjects [n=9], respectively; Figure 2B). Additional arterioles exposed to TMRM confirmed our JC-1 findings (224±70 versus 56±21 AU for T2DM [n=8] and nondiabetic subjects [n=8]).
respectively; Figure 2C). There was a strong trend toward increased mitochondria specific superoxide in arterioles from patients with T2DM (43±5 versus 26±7 AU for T2DM [n=10] and nondiabetic subjects [n=9], respectively; *P=0.05 versus nondiabetic subjects; Figure 2D). In an additional 5 T2DM and 4 non-T2DM subjects, treatment of arterioles for 30 minutes with 100 nmol/L CCCP resulted in significant reductions in mitochondrial superoxide levels in both subjects with and without T2DM (Figure 2E). Representative images for this experiment are included in Figure IV in the online-only Data Supplement.

**Effect of Partial Mitochondrial Uncoupling and Mitochondrial Antioxidant Exposure on Human Arteriolar Endothelial Function in T2DM and Nondiabetic Subjects**

Subcutaneous arterioles isolated from patients with T2DM demonstrate impaired endothelium-dependent vasodilation compared with nondiabetic controls (*P<0.001; Figure 3A). L-NAME completely inhibits Ach-induced endothelium-dependent vasodilation in these vessels in both T2DM patients and non-T2DM controls (Figure 3A). Thirty to sixty minutes of exposure of T2DM arterioles to 100 nmol/L of mitochondrial uncoupler CCCP to reduce \( \Delta \psi_m \) magnitude completely reversed endothelial dysfunction in T2DM arterioles (*P=0.02; Figure 3B). Cotreatment with L-NAME abrogated the beneficial effect of CCCP (Figure 3C). A different uncoupling agent, DNP, also reversed endothelial dysfunction in T2DM vessels (Figure 3D). CCCP (*P=0.94) and DNP had no effect on Ach-induced vasodilation of vessels from nondiabetic subjects. There were no significant differences in the Ach response in T2DM vessels exposed to CCCP compared with those exposed to DNP (*P=0.21). No differences in papaverine responses were seen between T2DM and nondiabetic subjects, regardless of CCCP or DNP exposure state. In an additional 4 T2DM subjects, we found that NO bioavailability significantly increased in arterioles from T2DM vessels after exposure to 100 nm CCCP (*P=0.03 overall by mixed ANOVA). *P<0.05 vs nondiabetics, †P=0.05 vs nondiabetes (E). Error bars represent ±SE.

**Figure 2. Comparisons of measurements of mitochondrial homeostasis in the arterioles of humans with and without type 2 diabetes mellitus (T2DM).** The arteriolar endothelium of patients with T2DM had significantly reduced mitochondria mass as reflected by reduced acridine orange 10-nonyl bromide (NAO) fluorescence (54±24 vs 199±58 AU, n=10 and 11 for T2DM and non-T2DM, respectively; *P=0.04) (A), increased \( \Delta \psi_m \) by both JC-1 (2.26±0.08 vs 1.91±0.06, n=5 and 9 for T2DM and non-T2DM, respectively; *P=0.01) (B) and tetramethylrhodamine methyl ester (TMRM) (224±70 vs 56±21 AU, n=8 and 8 for T2DM and non-T2DM, respectively; *P=0.04) (C). A strong trend toward an increase in mitochondrial superoxide was also seen in T2DM arterioles vs control subjects (43±5 vs 26±7 AU, n=10 and 9 for T2DM and non-T2DM, respectively; *P=0.05) (D). Treatment with carbonyl cyanide m-chlorophenyl hydrazone (CCCP) (100 nmol/L) significantly reduced mitochondrial superoxide production in both T2DM subjects (61±42 and 42±31 for T2DM and T2DM+CCCP, respectively, n=5) and non-T2DM subjects (37±27 and 22±10 for non-DM and non-DM+CCCP, respectively, n=4) (*P=0.002 overall by mixed ANOVA). *P<0.05 vs nondiabetics, †P=0.05 vs nondiabetes (E). Error bars represent ±SE.
Discussion

Our studies reveal several substantial findings linking T2DM-associated mitochondrial dysfunction with human arterial endothelial dysfunction. In arterioles from subjects with T2DM, we observed mitochondrial hyperpolarization, reduced mitochondrial mass, and excessive mitochondrial superoxide production relative to nondiabetic controls. These alterations in mitochondrial function were associated with impaired endothelium-dependent vasodilation to Ach, which with limited data, seems to be most associated with glycemic control. Two different treatments that reduce Δψₘ magnitude as well as a mitochondrial-specific superoxide scavenger improved NO synthase–dependent endothelial function in arterioles from patients with type 2 diabetes mellitus (T2DM). Impairment in endothelial function in T2DM arterioles is eNOS dependent (n=8 for T2DM and n=8 for controls). *P<0.05 vs T2DM alone only (A). Exposure to 100 nmol/L carbonyl cyanide m-chlorophenyl hydrazone (CCCP) for 30 minutes reverses T2DM-related endothelial dysfunction (n=6 controls, n=6 T2DM), *P<0.001 overall and *P=0.002 and 0.71 between curves with and without CCCP for T2DM and non-T2DM subjects, respectively. *P<0.05 vs all other exposures at the indicated Ach concentrations, †P<0.05 vs non-T2DM+L-NAME at the indicated acetylcholine [Ach] dose (A). Improved endothelial dysfunction with CCCP is related to improved eNOS activity (n=5 controls, n=6 T2DM). *P<0.001 between curves with and without L-NAME for both T2DM and non-T2DM subjects, *P<0.05 for both nondiabetic+CCCP+L-NAME and diabetes mellitus+CCCP+L-NAME vs both nondiabetic+CCCP and T2DM+CCCP. †P<0.05 for T2DM+CCCP vs nondiabetic+CCCP (C). Exposure to 50 nmol/L 2,4-dinitrophenol (DNP) also improved endothelial function in T2DM arterioles (n=7 controls, n=6 T2DM). P<0.05 overall, P=0.01 and P=0.44 between curves with and without DNP for T2DM and non-T2DM subjects, respectively. *P<0.05 vs all other exposures at the indicated Ach dose. †P<0.05 vs T2DM alone only (D). PAP indicates papaverine. Error bars represent ±SE.

(ρ=-0.59, P=0.01) between glycosylated hemoglobin levels and vasodilation to peak dose Ach (10⁻⁵ mol/L). When stratified by T2DM status, the statistical significance of the correlations is most likely due to small numbers but the strong negative directionality remained (ρ=-0.33 and -0.50, P=0.36 and 0.20 for T2DM and non-T2DM, respectively). For the n=42 (17 T2DM, 22 non-T2DM) paired fasting plasma glucose and peak dose Ach-paired measurements, fasting glucose strongly negatively correlated with peak dose Ach dose vasodilation as well (ρ=-0.49, P=0.001). However, when stratified by T2DM status, these correlations were significantly weakened (ρ=-0.10 and -0.08, P=0.67 and 0.74 for T2DM and non-T2DM, respectively).
measurements made in easily obtainable circulating cells relate to noninvasive measures of endothelial vasomotor function.

Patients with T2DM exhibit both conduit vessel and microvascular endothelial dysfunction. Endothelial dysfunction in this population predates the development of T2DM in humans because hyperglycemia with and without prevalent insulin resistance can induce systemic endothelial dysfunction. Although the pathophysiological mechanisms of endothelial dysfunction in T2DM are yet to be fully elucidated, human cross-sectional studies examining other cell types strongly suggest that patients with T2DM have impaired mitochondrial function, with concomitant reductions in mitochondrial ATP production capacity and increased mitochondrial ROS production that predate their expression of phenotypical T2DM. Cell culture and animal work suggest that exposures to high glucose and free fatty acid levels impair endothelial function through induction of excessive mitochondrial oxidative stress. Overexpression of UCPs suppresses both Δψ<sub>m</sub> magnitude and mitochondrial superoxide, whereas suppression of UCPs increases mitochondrial ROS production. Overexpression of UCPs in a rat model is protective against free fatty acid–induced endothelial dysfunction and vascular inflammation, whereas decreased UCP-2 expression is associated with increased atherosclerosis in mouse models. Recent cross-sectional data suggest that a human loss-of-function UCP-2 polymorphism is associated with an adverse cardiovascular risk profile. Our data extend these reports by demonstrating the importance of Δψ<sub>m</sub> as a novel, rapid-acting regulator of arteriolar endothelial function in humans with T2DM. Furthermore, our data suggest that Δψ<sub>m</sub> likely alters the endothelial phenotype, at least in part, through modulating mitochondrial ROS production.

We observed reduced mitochondrial mass in arterioles from patients with T2DM relative to nondiabetic subjects. Furthermore, reduced mitochondrial mass was associated with impaired systemic endothelial function, whereas increased mitochondrial superoxide production was associated with both impaired systemic endothelial function and reduced mitochondrial mass. A growing body of work supports key links between cellular mitochondrial morphology and mass

Figure 4. Carbonyl cyanide m-chlorophenyl hydrazone (CCCP) exposure improved NO bioavailability in arterioles from humans with type 2 diabetes mellitus (T2DM); 61±24 vs 85±29 for diaminofluorescein diacetate (DAF2-DA) fluorescence without and with CCCP, respectively. *P=0.04 by paired t test. Error bars represent ±SE.

Figure 5. Effect of MitoTEMPOL on endothelium-dependent vasodilation in human arterioles from patients with type 2 diabetes mellitus (T2DM). MitoTEMPOL (1 mmol/L) for 30 minutes before vasodilator testing significantly improved arteriolar endothelial function (n=4), P<0.001 overall for interaction of acetylcholine (Ach) dose and MitoTEMPOL exposure (A). L-N<sub>(i)</sub>-nitroarginine methyl ester (L-NAME) significantly inhibits the ameliorative effect of MitoTEMPOL on T2DM Ach–induced vasodilation (P<0.001 overall between curves) (B). *P<0.005 between curves at the indicated doses of Ach. Error bars represent ±SE.
with ATP and ROS production in insulin-resistant states. Insulin-resistant offspring of humans with T2DM have reduced mitochondrial density and ATP production capacity and mononuclear cells from patients with T2DM have smaller, less complex mitochondria. Interestingly, endothelial NO synthase–dependent NO bioavailability in cell culture and animal models has been shown to be a central regulator of transcription factor PPAR-γ coactivator-1α–dependent mitochondrial biogenesis. NO-deficient mice develop obesity and insulin resistance in concert with reduced mitochondrial mass. Furthermore, in the endothelium, suppression of NO bioavailability leads to excessive mitochondrial superoxide production. Our data extend these findings to the human vasculature by correlating systemic reductions in mitochondrial mass with impairment of NO-dependent endothelial function as well as demonstrating a reduction in mitochondrial mass in the vascular endothelium of patients with T2DM.

Our studies have several limitations. First, the correlations between mitochondrial mass and in vivo measurements of endothelial function are relatively modest. However, the strengths of these correlations are similar to those for traditional cardiovascular risk factors and both FMD and PAT. Because of the study size, we cannot make clear determinations as to whether T2DM or non-T2DM subjects are driving these correlations. Our correlations among glycosylated hemoglobin, fasting glucose, and Ach-induced vasodilation involve a small sample size and need to be repeated in a larger data set to confirm our findings. Second, we cannot infer a causal relationship between reduced mitochondrial mass and endothelial dysfunction on the basis of our data alone. Further in vitro and potentially in vivo work to determine whether manipulations of mitochondrial mass alter endothelial function in humans will be necessary to fully elucidate this potential relationship. We could not withdraw medical therapy from patients with T2DM for >24 hours for ethical reasons. Although we cannot exclude medication effects on our arteriolar measurements, the only medication significantly influencing mononuclear cell measures of mitochondrial function was angiotensin II receptor blocker therapy in patients with T2DM. This therapy was associated with a significantly higher mitochondrial mass by NAO staining within the group with T2DM (241±106 [n=8] AU [n=27], P=0.05). We consider this finding to be hypothesis-generating only. In light of the relative insulin resistance of our control group, it is possible that the differences we observed between our T2DM and non-T2DM groups would be larger if the non-T2DM group had greater insulin sensitivity. We did not collect glycosylated hemoglobin data on these subjects; therefore, we cannot directly determine an association between our vessel findings and near-term glycemic control. Balanced against these limitations are the novelty of the findings and their potential implications for vascular regulation and therapeutic targets in T2DM- and hyperglycemia-associated vascular disease.

Conclusion

Our data demonstrate that mitochondrial hyperpolarization and excessive superoxide production are directly associated with the development and maintenance of vascular endothelial dysfunction in patients with T2DM. Furthermore, reduced mitochondrial mass is significantly associated with impaired NO-dependent endothelial function. Our work suggests mitochondrial dysfunction may play a particularly key role in the development of atherosclerosis and vascular complications in patients with T2DM. Future work to determine and evaluate the efficacy interventions targeted to reduce ΔΨm on mitochondrial ROS production, and increase mitochondrial mass in T2DM is warranted.

Acknowledgments

We thank Emily Arthur, Jennifer Mulkerin, and Dorothee Weihrauch for their help with data acquisition.

Sources of Funding

Dr Widlansky receives support from K23HL089326, HL081587, the Elsa Shoenich Medical Research Fund (Greater Milwaukee Foundation), and a T. Franklin Williams Scholars Award provided by Atlantic Philanthropies, the American Heart Association (Grant-in-Aid 10GRNT3880044), the John A. Hartford Foundation, and the Association of Specialty Physicians. This work was supported by the Clinical Translational Research Institute at the Medical College of Wisconsin and National Institutes of Health (NIH) grant 1UL1-RR031973. Drs Kizhakekuttu, Dharmashankar, and Wang have received support from a Ruth L. Kirschstein NIH T32 training grant (HL007792-15). Dr Gutterman is supported by HL094971 and HL080704. Dr Vita is supported by HL083269, HL083801, HL081587, and HL75795. The contents of this manuscript are solely the responsibility of the authors and do not necessarily represent the official views of the NIH.

Disclosures

None.

References


Adverse Alterations in Mitochondrial Function Contribute to Type 2 Diabetes Mellitus–Related Endothelial Dysfunction in Humans
Tinoy J. Kizhakekuttu, Jingli Wang, Kodlipet Dharmashankar, Rong Ying, David D. Gutterman, Joseph A. Vita and Michael E. Widlansky

Arterioscler Thromb Vasc Biol. 2012;32:2531-2539; originally published online August 9, 2012;
doi: 10.1161/ATVBAHA.112.256024
Arteriosclerosis, Thrombosis, and Vascular Biology is published by the American Heart Association, 7272 Greenville Avenue, Dallas, TX 75231
Copyright © 2012 American Heart Association, Inc. All rights reserved.
Print ISSN: 1079-5642. Online ISSN: 1524-4636

The online version of this article, along with updated information and services, is located on the World Wide Web at:
http://atvb.ahajournals.org/content/32/10/2531

Data Supplement (unedited) at:
http://atvb.ahajournals.org/content/suppl/2012/08/09/ATVBAHA.112.256024.DC1

Permissions: Requests for permissions to reproduce figures, tables, or portions of articles originally published in Arteriosclerosis, Thrombosis, and Vascular Biology can be obtained via RightsLink, a service of the Copyright Clearance Center, not the Editorial Office. Once the online version of the published article for which permission is being requested is located, click Request Permissions in the middle column of the Web page under Services. Further information about this process is available in the Permissions and Rights Question and Answer document.

Reprints: Information about reprints can be found online at:
http://www.lww.com/reprints

Subscriptions: Information about subscribing to Arteriosclerosis, Thrombosis, and Vascular Biology is online at:
http://atvb.ahajournals.org//subscriptions/
**Adverse Alterations in Mitochondrial Function Contribute to Type 2 Diabetes Induced Endothelial Dysfunction in Humans**

Tinoy J. Kizhakekuttu, MD, Jingli Wang, MD, PhD, Kodlipet Dharmashankar, Rong Ying, David D. Gutterman MD, Joseph A. Vita, MD Michael E. Widlansky, MD, MPH

1- Department of Medicine, Division of Cardiovascular Medicine, Medical College of Wisconsin
2- Department of Pharmacology, Medical College of Wisconsin
3- Evans Department of Medicine, Boston University School of Medicine
4- Linus Pauling Institute, Oregon State University

*-Each author contributed equally to the development of this manuscript

**Main Text Word Count: 616 + 2 Tables and 3 Figures**

**Running Title:** Diabetes, Mitochondria, and Endothelial Function
Supplemental Methods:

Digital Pulse Amplitude Tonometry

For each study, the PAT device pressure was set to the lower of 70 mmHg or 10 mmHg below diastolic pressure. Baseline pulse amplitude was measured in both index fingers for 2 minutes. A blood pressure cuff placed on one forearm (the “test” arm) was subsequently inflated to 200 mmHg or 50 mmHg above systolic pressure (whichever was higher) and held at this pressure for 5 minutes. The cuff pressure was subsequently released. Pulse amplitude was measured continuously in the index fingers of the test and control arms throughout the entire study and reported in 30 second intervals for 4 minutes following cuff release.

Human Arteriolar Acquisition and Preparation for Analysis of Endothelial Function

Human subcutaneous arterioles from non-diabetic and T2DM subjects were obtained by gluteal fat pad biopsy under local anesthesia (1% lidocaine) using sterile technique. Following sterilization and the use of local anesthesia, a small (~ 1 cm) incision was made into the gluteal fat pad approximately 2-3 cm medial and cephalad of the greater trochanter. Approximately 2 mL of fat tissue was removed by sharp dissection and incision closed with an absorbable suture and steristrips. The fat sample was transferred immediately into cold HEPES buffer (4°C) and taken for immediate analysis.

Arterioles were isolated and cleaned of fat and connective tissue. Vessel were subsequently transferred to an organ bath and cannulated with tapered glass micropipettes filled with Krebs buffer consisting of (in mM) 123 NaCl, 4.7 KCl, 2.5 CaCl2, 0.026 EDTA, 1.2 MgSO4, 20 NaHCO3, 1.2 KH2PO4, and 5 mM of glucose. The bath was subsequently transferred to the stage of an inverted microscope attached to a video camera and monitor with video calipers. The bath was continuously superfused with Krebs buffer bubbled with a gas
mixture of 21% O₂, 5% CO₂, and 74% N₂. Arterioles were allowed to equilibrate to an intra-luminal pressure of 20 mmHg supplied by a reservoir system for 30 minutes. The intra-luminal pressure was subsequently increased to 60 mmHg for 30 minutes. Following equilibration, vessels were pre-constricted to 50% of maximal diameter with endothelin-1.

**Supplemental Figure Legends:**

**Supplemental Figure I: Endothelial Specificity of JC-1 and NAO Fluorescence in Human Arterioles**  Using our protocol delineated in the methods section, we imaged 3 human arterioles by confocal microscopy focused on the endothelial cell layer following intra-luminal exposure to JC-1. Both red (a) and green (b) fluorescence intensity was significantly higher in intact arterioles exposed to JC-1 compared to vessels exposed to buffer alone or denuded of endothelium by air bolus following JC-1 exposure. (*-P=0.01 overall, P <0.05 vs. buffer alone and denuded vessel for both red and green JC-1 fluorescence). Similarly, we imaged 3 human arterioles following intra-luminal exposure to NAO (c). NAO fluorescence intensity was significantly greater in intact arterioles compared to those denuded of endothelium following NAO exposure (*-P=0.02).

**Supplemental Figure II: Sample images of from arteriolar studies using NAO (a-c) and JC-1 (d-f) demonstrating endothelial specificity of the protocols for these fluorophores.**

**Supplemental Figure III: MitoSox™ negatively correlated with NAO fluorescence intensity in human mononuclear cells isolated from peripheral venous blood (N=14).**

**Supplemental Figure IV: Representative MitoSox™ fluorescence images from arterioles from a single T2DM subject without CCCP exposure, (a), following 30 minutes of CCCP (100 nM) exposure (b), and a negative control vessel without exposure to DAF2-DA or CCCP (c).**
Similar without CCCP (d), with CCCP (100 nM) (e), and negative control images are shown for a non-T2DM subject.

**Supplemental Figure V:** Representative DAF2-DA (5 µM) fluorescence images from arterioles from a single T2DM subject without CCCP exposure, (a), following 30 minutes of CCCP (100 nM) exposure (b), and a negative control vessel without exposure to DAF2-DA or CCCP (c).
<table>
<thead>
<tr>
<th>Medication</th>
<th>Type 2 Diabetes</th>
<th>Non-Diabetics</th>
</tr>
</thead>
<tbody>
<tr>
<td>Insulin</td>
<td>11.7</td>
<td>0</td>
</tr>
<tr>
<td>Metformin</td>
<td>78.3</td>
<td>0</td>
</tr>
<tr>
<td>Sulfonylurea</td>
<td>35.0</td>
<td>0</td>
</tr>
<tr>
<td>Thiazoladinedione</td>
<td>6.7</td>
<td>0</td>
</tr>
<tr>
<td>Dipeptidyl peptidase-4 inhibitors</td>
<td>1.7</td>
<td>0</td>
</tr>
<tr>
<td>Incretin Mimetics</td>
<td>1.7</td>
<td>0</td>
</tr>
<tr>
<td>Beta-Blockers</td>
<td>20.0</td>
<td>0</td>
</tr>
<tr>
<td>ACE Inhibitors</td>
<td>30.0</td>
<td>0</td>
</tr>
<tr>
<td>Angiotensin-2 Receptor blockers</td>
<td>18.3</td>
<td>1.6</td>
</tr>
<tr>
<td>Calcium Channel Blockers</td>
<td>10.0</td>
<td>0</td>
</tr>
<tr>
<td>Diuretic</td>
<td>26.7</td>
<td>0</td>
</tr>
<tr>
<td>Hydralazine</td>
<td>3.3</td>
<td>0</td>
</tr>
<tr>
<td>Aspirin</td>
<td>33.3</td>
<td>3.2</td>
</tr>
<tr>
<td>HMG-CoA Reductase Inhibitors</td>
<td>38.3</td>
<td>0</td>
</tr>
<tr>
<td>NSAIDs</td>
<td>6.7</td>
<td>6.5</td>
</tr>
<tr>
<td>Multivitamins</td>
<td>30.0</td>
<td>22.6</td>
</tr>
<tr>
<td>Hormone Replacement Therapy</td>
<td>3.3%</td>
<td>6.5</td>
</tr>
</tbody>
</table>
### Supplemental Table II - *In Vivo* Measurements of Vascular Endothelial Function

<table>
<thead>
<tr>
<th></th>
<th>Type 2 Diabetes (N=60)</th>
<th>No Diabetes (N=62)</th>
<th>P-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Resting Brachial Diameter (cm)</td>
<td>3.9±0.7</td>
<td>3.7±0.7</td>
<td>0.21</td>
</tr>
<tr>
<td>Flow Mediated Dilation (%)</td>
<td>3.7±1.7</td>
<td>6.2±1.6</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Peak Resting Shear (dynes/cm²)</td>
<td>39.7±14.0</td>
<td>42.1±15.1</td>
<td>0.36</td>
</tr>
<tr>
<td>Peak Hyperemic Shear (dynes/cm²)</td>
<td>70.7±28.3</td>
<td>78.7±28.2</td>
<td>0.09</td>
</tr>
<tr>
<td>Nitroglycerin Mediated Dilation (%)*</td>
<td>19.5±6.3</td>
<td>21.9±7.0</td>
<td>0.07</td>
</tr>
<tr>
<td>Nitroglycerin Mediated Dilation (mm)</td>
<td>0.73±21</td>
<td>0.82±0.26</td>
<td>0.05</td>
</tr>
<tr>
<td>ln PAT (90-120 sec)†</td>
<td>0.48±0.42</td>
<td>0.74±0.61</td>
<td>0.02</td>
</tr>
</tbody>
</table>

*-*N=53 for T2DM, N=51 for non-diabetics

†-N=43 with T2DM, N=47 for non-diabetics
### Supplemental Table III- Resting Diameters of Human Arterioles Pre and Post Exposure to Pharmacological Agents

<table>
<thead>
<tr>
<th>Pharmacological Agent</th>
<th>Resting Diameter (nm) Prior to Exposure</th>
<th>Resting Diameter (nm) Post Exposure</th>
<th>P-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>CCCP (n=12)</td>
<td>123±74</td>
<td>121±71</td>
<td>0.94</td>
</tr>
<tr>
<td>DNP (n=13)</td>
<td>101±46</td>
<td>93±48</td>
<td>0.67</td>
</tr>
<tr>
<td>MitoTEMPOL (n=4)</td>
<td>64±27</td>
<td>61±27</td>
<td>0.84</td>
</tr>
</tbody>
</table>

All data mean±SD
Supplemental Figure III

\[ \rho = -0.72, \ P = 0.006 \]
Adverse Alterations in Mitochondrial Function Contribute to Type 2 Diabetes Induced Endothelial Dysfunction in Humans

Tinoy J. Kizhakekuttu, MD, Jingli Wang, MD, PhD, Kodlipet Dharmashankar, Rong Ying, David D. Gutterman MD, Joseph A. Vita, MD Michael E. Widlansky, MD, MPH

1- Department of Medicine, Division of Cardiovascular Medicine, Medical College of Wisconsin
2- Department of Pharmacology, Medical College of Wisconsin
3- Evans Department of Medicine, Boston University School of Medicine
4- Linus Pauling Institute, Oregon State University

*Each author contributed equally to the development of this manuscript

Main Text Word Count: 616 + 2 Tables and 3 Figures

Running Title: Diabetes, Mitochondria, and Endothelial Function
Supplemental Methods:

Digital Pulse Amplitude Tonometry

For each study, the PAT device pressure was set to the lower of 70 mmHg or 10 mmHg below diastolic pressure. Baseline pulse amplitude was measured in both index fingers for 2 minutes. A blood pressure cuff placed on one forearm (the “test” arm) was subsequently inflated to 200 mmHg or 50 mmHg above systolic pressure (whichever was higher) and held at this pressure for 5 minutes. The cuff pressure was subsequently released. Pulse amplitude was measured continuously in the index fingers of the test and control arms throughout the entire study and reported in 30 second intervals for 4 minutes following cuff release.

Human Arteriolar Acquisition and Preparation for Analysis of Endothelial Function

Human subcutaneous arterioles from non-diabetic and T2DM subjects were obtained by gluteal fat pad biopsy under local anesthesia (1% lidocaine) using sterile technique. Following sterilization and the use of local anesthesia, a small (~1 cm) incision was made into the gluteal fat pad approximately 2-3 cm medial and cephalad of the greater trochanter. Approximately 2 mL of fat tissue was removed by sharp dissection and incision closed with an absorbable suture and steristrips. The fat sample was transferred immediately into cold HEPES buffer (4°C) and taken for immediate analysis.

Arterioles were isolated and cleaned of fat and connective tissue. Vessel were subsequently transferred to an organ bath and cannulated with tapered glass micropipettes filled with Krebs buffer consisting of (in mM) 123 NaCl, 4.7 KCl, 2.5 CaCl₂, 0.026 EDTA, 1.2 MgSO₄, 20 NaHCO₃, 1.2 KH₂PO₄, and 5 mM of glucose. The bath was subsequently transferred to the stage of an inverted microscope attached to a video camera and monitor with video calipers. The bath was continuously superfused with Krebs buffer bubbled with a gas
mixture of 21% O₂, 5% CO₂, and 74% N₂. Arterioles were allowed to equilibrate to an intra-luminal pressure of 20 mmHg supplied by a reservoir system for 30 minutes. The intra-luminal pressure was subsequently increased to 60 mmHg for 30 minutes. Following equilibration, vessels were pre-constricted to 50% of maximal diameter with endothelin-1.

Supplemental Figure Legends:

Supplemental Figure I: Endothelial Specificity of JC-1 and NAO Fluorescence in Human Arterioles Using our protocol delineated in the methods section, we imaged 3 human arterioles by confocal microscopy focused on the endothelial cell layer following intra-luminal exposure to JC-1. Both red (a) and green (b) fluorescence intensity was significantly higher in intact arterioles exposed to JC-1 compared to vessels exposed to buffer alone or denuded of endothelium by air bolus following JC-1 exposure. (*-P=0.01 overall, P <0.05 vs. buffer alone and denuded vessel for both red and green JC-1 fluorescence). Similarly, we imaged 3 human arterioles following intra-luminal exposure to NAO (c). NAO fluorescence intensity was significantly greater in intact arterioles compared to those denuded of endothelium following NAO exposure (*-P=0.02).

Supplemental Figure II: Sample images of from arteriolar studies using NAO (a-c) and JC-1 (d-f) demonstrating endothelial specificity of the protocols for these fluorophores.

Supplemental Figure III: MitoSox™ negatively correlated with NAO fluorescence intensity in human mononuclear cells isolated from peripheral venous blood (N=14).

Supplemental Figure IV: Representative MitoSox™ fluorescence images from arterioles from a single T2DM subject without CCCP exposure, (a), following 30 minutes of CCCP (100 nM) exposure (b), and a negative control vessel without exposure to DAF2-DA or CCCP (c).
Similar without CCCP (d), with CCCP (100 nM) (e), and negative control images are shown for a non-T2DM subject.

**Supplemental Figure V:** Representative DAF2-DA (5 µM) fluorescence images from arterioles from a single T2DM subject without CCCP exposure, (a), following 30 minutes of CCCP (100 nM) exposure (b), and a negative control vessel without exposure to DAF2-DA or CCCP (c).
Supplemental Table I – Percentage of Subjects Taking Medications from Listed Classes

<table>
<thead>
<tr>
<th>Medication</th>
<th>Type 2 Diabetes</th>
<th>Non-Diabetics</th>
</tr>
</thead>
<tbody>
<tr>
<td>Insulin</td>
<td>11.7</td>
<td>0</td>
</tr>
<tr>
<td>Metformin</td>
<td>78.3</td>
<td>0</td>
</tr>
<tr>
<td>Sulfonylurea</td>
<td>35.0</td>
<td>0</td>
</tr>
<tr>
<td>Thiazoladinedione</td>
<td>6.7</td>
<td>0</td>
</tr>
<tr>
<td>Dipeptidyl peptidase-4 inhibitors</td>
<td>1.7</td>
<td>0</td>
</tr>
<tr>
<td>Incretin Mimetics</td>
<td>1.7</td>
<td>0</td>
</tr>
<tr>
<td>Beta-Blockers</td>
<td>20.0</td>
<td>0</td>
</tr>
<tr>
<td>ACE Inhibitors</td>
<td>30.0</td>
<td>0</td>
</tr>
<tr>
<td>Angiotensin-2 Receptor blockers</td>
<td>18.3</td>
<td>1.6</td>
</tr>
<tr>
<td>Calcium Channel Blockers</td>
<td>10.0</td>
<td>0</td>
</tr>
<tr>
<td>Diuretic</td>
<td>26.7</td>
<td>0</td>
</tr>
<tr>
<td>Hydralazine</td>
<td>3.3</td>
<td>0</td>
</tr>
<tr>
<td>Aspirin</td>
<td>33.3</td>
<td>3.2</td>
</tr>
<tr>
<td>HMG-CoA Reductase Inhibitors</td>
<td>38.3</td>
<td>0</td>
</tr>
<tr>
<td>NSAIDs</td>
<td>6.7</td>
<td>6.5</td>
</tr>
<tr>
<td>Multivitamins</td>
<td>30.0</td>
<td>22.6</td>
</tr>
<tr>
<td>Hormone Replacement Therapy</td>
<td>3.3%</td>
<td>6.5</td>
</tr>
</tbody>
</table>
Supplemental Table II- *In Vivo* Measurements of Vascular Endothelial Function

<table>
<thead>
<tr>
<th>Measure</th>
<th>Type 2 Diabetes <em>(N=60)</em></th>
<th>No Diabetes <em>(N=62)</em></th>
<th>P-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Resting Brachial Diameter (cm)</td>
<td>3.9±0.7</td>
<td>3.7±0.7</td>
<td>0.21</td>
</tr>
<tr>
<td>Flow Mediated Dilation (%)</td>
<td>3.7±1.7</td>
<td>6.2±1.6</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Peak Resting Shear (dynes/cm²)</td>
<td>39.7±14.0</td>
<td>42.1±15.1</td>
<td>0.36</td>
</tr>
<tr>
<td>Peak Hyperemic Shear (dynes/cm²)</td>
<td>70.7±28.3</td>
<td>78.7±28.2</td>
<td>0.09</td>
</tr>
<tr>
<td>Nitroglycerin Mediated Dilation (%)*</td>
<td>19.5±6.3</td>
<td>21.9±7.0</td>
<td>0.07</td>
</tr>
<tr>
<td>Nitroglycerin Mediated Dilation (mm)</td>
<td>0.73±21</td>
<td>0.82±0.26</td>
<td>0.05</td>
</tr>
<tr>
<td>ln PAT (90-120 sec)*†</td>
<td>0.48±0.42</td>
<td>0.74±0.61</td>
<td>0.02</td>
</tr>
</tbody>
</table>

*-N=53 for T2DM, N=51 for non-diabetics

†-N=43 with T2DM, N=47 for non-diabetics
Supplemental Table III- Resting Diameters of Human Arterioles Pre and Post Exposure to Pharmacological Agents

<table>
<thead>
<tr>
<th></th>
<th>Resting Diameter (nm) Prior to Exposure</th>
<th>Resting Diameter (nm) Post Exposure</th>
<th>P-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>CCCP (n=12)</td>
<td>123±74</td>
<td>121±71</td>
<td>0.94</td>
</tr>
<tr>
<td>DNP (n=13)</td>
<td>101±46</td>
<td>93±48</td>
<td>0.67</td>
</tr>
<tr>
<td>MitoTEMPO (n=4)</td>
<td>64±27</td>
<td>61±27</td>
<td>0.84</td>
</tr>
</tbody>
</table>

All data mean±SD
Supplemental Figure II

a) Buffer Only  
b) NAO Endo(+)  
c) NAO Endo (-)  
d) Buffer Only  
e) JC-1 Endo(+)  
f) JC-1 Endo (-)
Supplemental Figure III

\[
\rho = -0.72, \ P = 0.006
\]